Taysha Gene Therapies EBITDA Margin 2020-2024 | TSHA
Current and historical EBITDA (Earnings Before Interest, Taxes, Depreciation and Amortization) margin for Taysha Gene Therapies (TSHA) over the last 10 years. The current EBITDA margin for Taysha Gene Therapies as of September 30, 2024 is .
| Taysha Gene Therapies EBITDA Margin Historical Data |
| Date |
TTM Revenue |
TTM EBITDA |
EBITDA Margin |
| 2024-09-30 |
$0.01B |
$-0.09B |
-870.00% |
| 2024-06-30 |
$0.01B |
$-0.08B |
-592.31% |
| 2024-03-31 |
$0.01B |
$-0.08B |
-564.29% |
| 2023-12-31 |
$0.02B |
$-0.07B |
-443.75% |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.379B |
$0.015B |
|
Taysha Gene Therapies Inc. is a patient-centric gene therapy company. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system. The company's product pipeline includes TSHA-101, TSHA-118, TSHA-102, TSHA-103 and TSHA-104 which are in clinical stage. Taysha Gene Therapies Inc. is based in Dallas, Texas.
|
